BLFS Insider Trading

Insider Ownership Percentage: 2.20%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $4,979,016.72

BioLife Solutions Insider Trading History Chart

This chart shows the insider buying and selling history at BioLife Solutions by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$1.20MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$10M-$5M$0$5M$10MTotal Insider BuyingTotal Insider Selling

BioLife Solutions Share Price & Price History

Current Price: $21.91
Price Change: Price Decrease of -0.35 (-1.57%)
As of 04/17/2025 05:00 PM ET

This chart shows the closing price history over time for BLFS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$21.91Closing price on 04/18/25:

SEC Filings (Institutional Ownership Changes) for BioLife Solutions (NASDAQ:BLFS)

93.24% of BioLife Solutions stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at BLFS by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$2.14Mbought$287ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$50M$0$50MTotal InflowsTotal Outflows
BioLife Solutions logo
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Read More on BioLife Solutions

Today's Range

Now: $21.91
Low: $21.77
High: $22.60

50 Day Range

MA: $24.62
Low: $20.64
High: $28.32

52 Week Range

Now: $21.91
Low: $15.42
High: $29.55

Volume

529,574 shs

Average Volume

375,729 shs

Market Capitalization

$1.04 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.93

Who are the company insiders with the largest holdings of BioLife Solutions?

BioLife Solutions' top insider investors include:
  1. Casdin Partners Master Fund, L (Major Shareholder)
  2. Greef Roderick De (CEO)
  3. Michael Rice (CEO)
  4. Aby J Mathew (EVP)
  5. Troy Wichterman (CFO)
  6. Karen A Foster (Insider)
  7. Todd Berard (CMO)
  8. Garrie Richardson (CRO)
  9. Sarah Aebersold (Insider)
  10. Geraint Phillips (SVP)
  11. Marcus Schulz (CRO)
  12. Amy Duross (Director)
  13. Sean Werner (CTO)
Learn More about top insider investors at BioLife Solutions.

Who are the major institutional investors of BioLife Solutions?

BioLife Solutions' top institutional investors include:
  1. GAMMA Investing LLC — 0.21%
  2. Rhumbline Advisers — 0.18%
  3. Kings Path Partners LLC — 0.04%
  4. SG Americas Securities LLC — 0.04%
  5. GAMMA Investing LLC — 0.01%
Learn More about top institutional investors of BioLife Solutions stock.

Which institutional investors are selling BioLife Solutions stock?

During the last quarter, BLFS stock was sold by these institutional investors:
  1. Kings Path Partners LLC
Within the last year, company insiders that have sold BioLife Solutions company stock include:
  1. Casdin Partners Master Fund, L (Major Shareholder)
  2. Greef Roderick De (CEO)
  3. Michael Rice (CEO)
  4. Aby J Mathew (EVP)
  5. Troy Wichterman (CFO)
  6. Karen A Foster (Insider)
  7. Todd Berard (CMO)
  8. Garrie Richardson (CRO)
Learn More investors selling BioLife Solutions stock.

Which institutional investors are buying BioLife Solutions stock?

Within the last quarter, BLFS stock was bought by institutional investors including:
  1. GAMMA Investing LLC
  2. SG Americas Securities LLC
  3. GAMMA Investing LLC
  4. Rhumbline Advisers